組換えDNA技術市場規模、シェア、成長分析：製品別、コンポーネント別、用途別、最終用途別、地域別 - 産業予測 2025～2032年

組換えDNA技術の世界市場規模は、2023年に1,555億米ドルと評価され、2024年の1,671億6,000万米ドルから2032年には2,981億3,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは7.5%で成長する見通しです。

組換えDNA（rDNA）技術は遺伝子データ管理を一変させ、バイオテクノロジーや製薬の分野での様々な応用を可能にしました。最近の進歩により、糖尿病管理用の遺伝子組み換えインスリンの商業的成功に代表されるように、ヒトドナーを必要としない組換え医薬品の生産が可能になりました。慢性疾患のコストが上昇する中、業界は革新的な治療ソリューションのためにrDNA法を活用しています。特にCRISPR/Cas9、ZFN、TALEN技術を用いた組換えタンパク質の開発が進んでおり、バイオ医薬品の進歩と精密ゲノム編集を強化しています。さらに、遺伝子組み換え作物の作付面積が世界的に拡大していることは、農業におけるrDNAの成功を裏付けており、その応用範囲はバイオ燃料や環境課題のための生物農薬にまで広がっています。しかし、遺伝子治療や技術利用に関する倫理的な懸念は、さまざまな分野で現在進行中の議論となっています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

組換えDNA技術市場規模：製品別& CAGR（2025-2032）

• 市場概要
• 医療
  • 治療薬
  • ヒトタンパク質
  • ワクチン
• 非医療
  • バイオテクノロジー作物
  • 特殊化学品
  • その他の非医療製品

組換えDNA技術市場規模：コンポーネント別& CAGR（2025-2032）

• 市場概要
• 発現システム
  • 哺乳類
  • 細菌
  • 酵母
  • バキュロウイルス/昆虫
  • その他の発現システム
• クローニングベクター

組換えDNA技術市場規模：用途別& CAGR（2025-2032）

• 市場概要
• 食品と農業
• 健康と病気
  • 人間
  • 動物
• 環境
• その他の用途

組換えDNA技術市場規模：最終用途別& CAGR（2025-2032）

• 市場概要
• バイオテクノロジーおよび製薬企業
• 学術機関および政府調査機関
• その他の最終用途

組換えDNA技術市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Thermo Fisher Scientific（US）
• Roche Holding AG（Switzerland）
• Merck KGaA（Germany）
• Agilent Technologies（US）
• Bio-Rad Laboratories（US）
• Illumina（US）
• Danaher Corporation（US）
• Sartorius AG（Germany）
• Lonza Group（Switzerland）
• Charles River Laboratories（US）
• GenScript Biotech Corporation（China）
• Twist Bioscience（US）
• Ginkgo Bioworks（US）
• Amyris（US）
• Synthetic Genomics（US）
• Intrexon（US）
• PerkinElmer（US）
• Eurofins Scientific（Luxembourg）

結論と提言

Global Recombinant DNA Technology Market size was valued at USD 155.5 billion in 2023 and is poised to grow from USD 167.16 billion in 2024 to USD 298.13 billion by 2032, growing at a CAGR of 7.5% during the forecast period (2025-2032).

Recombinant DNA (rDNA) technology has transformed genetic data control, allowing for various applications across the biotech and pharmaceutical landscapes. Recent advancements have enabled the successful production of recombinant medications without human donors, highlighted by the commercial success of genetically modified insulin for diabetes management. As chronic disease costs rise, the industry is leveraging rDNA methods for innovative therapeutic solutions. The ongoing development of recombinant proteins, particularly using CRISPR/Cas9, ZFN, and TALEN technologies, enhances biopharmaceutical advancements and precision genome editing. Additionally, the global expansion of GM crop acreage underscores rDNA's success in agriculture, with applications extending to biofuels and biopesticides for environmental challenges. However, ethical concerns regarding gene therapy and technology usage present ongoing debates across various sectors.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Recombinant Dna Technology market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Recombinant Dna Technology Market Segments Analysis

Global Recombinant DNA Technology Market is segmented by Product, Component, Application, End Use and region. Based on Product, the market is segmented into Medical and Non-medical. Based on Component, the market is segmented into Expression System and Cloning Vector. Based on Application, the market is segmented into Food & Agriculture, Health & Disease, Environment and Other Applications. Based on End Use, the market is segmented into Biotechnology and Pharmaceutical Companies, Academic & Government Research Institutes and Other End Uses. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Recombinant Dna Technology Market

The growth of the global recombinant DNA technology market during the forecast period is anticipated to be significantly influenced by an increase in strategic partnerships among major industry players. These collaborations aim to advance the development of recombinant DNA technologies and often involve partnerships with prominent biopharmaceutical companies and research institutions to create innovative therapeutics. Such collective efforts and strategic alliances within the market are expected to facilitate advancements and drive expansion in the sector, leading to new opportunities and a heightened competitive landscape in the field of recombinant DNA technology.

Restraints in the Global Recombinant Dna Technology Market

The growth of the Global Recombinant DNA Technology market is being hindered by several factors, primarily the high costs associated with gene therapy. Additionally, potential side effects, such as Cytokine Release Syndrome (CRS) and neurotoxicity, pose significant challenges. The anticipated expansion of the market is further limited by various ethical, legal, and scientific constraints surrounding gene therapy applications. These restrictions not only impact research and development efforts but also contribute to hesitation among stakeholders, ultimately affecting the overall progress and acceptance of recombinant DNA technologies within the healthcare landscape.

Market Trends of the Global Recombinant Dna Technology Market

The Global Recombinant DNA Technology market is witnessing a significant upward trend driven by increasing public acceptance of genetically modified crops aimed at enhancing agricultural yield and pest resistance. Pioneering initiatives, such as the licensing of the genetically modified tomato CGN-89564-2 for human consumption, are paving the way for broader applications across various sectors. The intersection of DNA molecular marker technologies further facilitates the identification and innovation of valuable plant germplasm resources. This surge in research and application of GMOs, particularly in food, agriculture, and medicine, underscores the potential of recombinant DNA technology to revolutionize health care and biomedicine, creating lucrative opportunities for market stakeholders.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Recombinant DNA Technology Market Size by Product & CAGR (2025-2032)

• Market Overview
• Medical
  • Therapeutic Agent
  • Human Protein
  • Vaccine
• Non-medical
  • Biotech Crops
  • Specialty Chemicals
  • Other Non-medical Products

Global Recombinant DNA Technology Market Size by Component & CAGR (2025-2032)

• Market Overview
• Expression System
  • Mammalian
  • Bacteria
  • Yeast
  • Baculovirus / Insect
  • Other Expression Systems
• Cloning Vector

Global Recombinant DNA Technology Market Size by Application & CAGR (2025-2032)

• Market Overview
• Food & Agriculture
• Health & Disease
  • Human
  • Animal
• Environment
• Other Applications

Global Recombinant DNA Technology Market Size by End Use & CAGR (2025-2032)

• Market Overview
• Biotechnology and Pharmaceutical Companies
• Academic & Government Research Institutes
• Other End Uses

Global Recombinant DNA Technology Market Size & CAGR (2025-2032)

• North America (Product, Component, Application, End Use)
  • US
  • Canada
• Europe (Product, Component, Application, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Component, Application, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Component, Application, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Component, Application, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Thermo Fisher Scientific (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sartorius AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza Group (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GenScript Biotech Corporation (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Twist Bioscience (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ginkgo Bioworks (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amyris (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Synthetic Genomics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intrexon (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific (Luxembourg)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations